Merck touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis ...

Connect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce ...

Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling ...

Base editing biotech Beam Therapeutics is suing one of its newest rivals, alleging that the upstart company stole the secrets ...

Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the ...

Highlight Therapeutics touted positive topline results in patients with localized high-risk head and neck basal cell ...

Amgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose. | Amgen has shed light on its ...

UniQure filed for accelerated FDA approval early this month. (uniQure) uniQure’s Huntington’s disease gene therapy has failed ...

The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor ...

Merck paid Daiichi $4 billion upfront in 2023 to partner on three ADCs. The FDA rejected a request for approval of one of the ...

Precision Neurosciences, which specializes in brain-computer interface technology, raised $250 million in an oversubscribed ...

A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, ...